Health and Healthcare
Cell Genesys Scores $30 Million Premium Financing (CEGE)
Published:
Last Updated:
Cell Genesys, Inc. (NASDAQ: CEGE) plans to offer 7.1 million shares of common stock and warrants at an equivalent of $4.22 per share with a single institutional investor, for an equity offering valued at approximately $30 million.
The warrants will have a strike price of $10.00 and can purchase 8.5 million shares. The proceeds from the offering will be used to finance developmental products such as its GVAX treatment for prostate cancer, as well as for general corporate purposes.
The offering is expected to close Wednesday. Credit Suisse Securities LLC is the lead placement agent for the offering.
The cancer focused biotech company is trading down over 3% in early morning trading at $3.77. The market cap sits at approximately $300 million and the 52-week range spans $1.78 to $4.71.
You can also sign up to our open email distribution list to see about other secondary offerings, IPO’s, break-ups, spin-offs, and more.
Rachel Lopez
May 12, 2008
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
